Test Research, Inc.

TWSE:3030 Stock Report

Market Cap: NT$61.2b

Test Research Balance Sheet Health

Financial Health criteria checks 6/6

Test Research has a total shareholder equity of NT$9.7B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$14.8B and NT$5.1B respectively. Test Research's EBIT is NT$3.5B making its interest coverage ratio -272.1. It has cash and short-term investments of NT$2.4B.

Key information

0%

Debt to equity ratio

NT$0

Debt

Interest coverage ratio-272.1x
CashNT$2.42b
EquityNT$9.73b
Total liabilitiesNT$5.08b
Total assetsNT$14.81b

Recent financial health updates

No updates

Recent updates

Analysis Article • Oct 17

Capital Investment Trends At Test Research (TWSE:3030) Look Strong

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analysis Article • Aug 05

Test Research, Inc.'s (TWSE:3030) Popularity With Investors Under Threat As Stock Sinks 27%

Test Research, Inc. ( TWSE:3030 ) shares have retraced a considerable 27% in the last month, reversing a fair amount of...
Analysis Article • Jul 11

Test Research (TWSE:3030) May Have Issues Allocating Its Capital

Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Analysis Article • Jun 01

Test Research (TWSE:3030) Has Announced That Its Dividend Will Be Reduced To NT$3.30

Test Research, Inc. ( TWSE:3030 ) is reducing its dividend from last year's comparable payment to NT$3.30 on the 5th of...
Analysis Article • May 31

Optimistic Investors Push Test Research, Inc. (TWSE:3030) Shares Up 67% But Growth Is Lacking

Despite an already strong run, Test Research, Inc. ( TWSE:3030 ) shares have been powering on, with a gain of 67% in...
Analysis Article • Apr 15

Test Research, Inc.'s (TWSE:3030) 25% Share Price Surge Not Quite Adding Up

Despite an already strong run, Test Research, Inc. ( TWSE:3030 ) shares have been powering on, with a gain of 25% in...
Analysis Article • Mar 19

Is Test Research, Inc. (TPE:3030) A Smart Choice For Dividend Investors?

Is Test Research, Inc. ( TPE:3030 ) a good dividend stock? How can we tell? Dividend paying companies with growing...
Analysis Article • Mar 01

With EPS Growth And More, Test Research (TPE:3030) Is Interesting

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...
Analysis Article • Feb 11

Should You Invest In Test Research (TPE:3030)?

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Analysis Article • Jan 24

Test Research (TPE:3030) Has Compensated Shareholders With A Respectable 70% Return On Their Investment

The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...
Analysis Article • Jan 05

Is Test Research, Inc.'s (TPE:3030) Latest Stock Performance Being Led By Its Strong Fundamentals?

Test Research's (TPE:3030) stock up by 1.9% over the past week. Since the market usually pay for a company’s long-term...
Analysis Article • Dec 18

Is Test Research, Inc. (TPE:3030) A Good Dividend Stock?

Could Test Research, Inc. ( TPE:3030 ) be an attractive dividend share to own for the long haul? Investors are often...
Analysis Article • Nov 30

Here's Why I Think Test Research (TPE:3030) Is An Interesting Stock

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...

Financial Position Analysis

Short Term Liabilities: 3030's short term assets (NT$10.3B) exceed its short term liabilities (NT$4.8B).

Long Term Liabilities: 3030's short term assets (NT$10.3B) exceed its long term liabilities (NT$328.3M).

Debt to Equity History and Analysis

Debt Level: 3030 is debt free.

Reducing Debt: 3030 has not had any debt for past 5 years.

Debt Coverage: 3030 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 3030 has no debt, therefore coverage of interest payments is not a concern.

Balance Sheet

Discover healthy companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/14 17:14
End of Day Share Price 2026/09/14 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Test Research, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrea SuCLSA
null nullSinoPac Securities Investment Service
Chia-Chi ChangYuanta Research